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Coumarin derivatives possess a wide spectrum of biological activities (1–3). Also, it
is well documented that pyrazoles, pyrazolin-5-ones, 4-thiazolidinones and 1,3,4-oxadia-
zoles display pronounced antioxidant (4–6) and antineoplastic activity (7–10). In view of
the considerable importance of the coumarins and heterocycles mentioned above, the
present work is aimed at the design and synthesis of new heterocyclic compounds bear-
ing coumarin moiety. Moreover, the study includes testing of target compounds for their
cytotoxic activity against Dalton’s lymphoma ascites (DLA) and Ehrlich ascites carcino-
ma (EAC) cells.
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The aim of the present work was to synthesise couma-
rinyl heterocycles and to elucidate the potential role of
these compounds as antioxidants and cytotoxic agents
against Dalton’s lymphoma ascites tumour cells (DLA)
and Ehrlich ascites carcinoma cells (EAC). The synthesis
of coumarin derivatives containing pyrazole, pyrazolone,
thiazolidin-4-one, 5-carboxymethyl-4-thiazolidinone and
3-acetyl-1,3,4-oxadiazole ring is reported. 4-Methylcou-
marinyl-7-oxyacetic acid hydrazide (1) reacted with aryl-
azopropanes or hydrazono-3-oxobutyrate derivatives to
form pyrazole (3a-c) and pyrazolone derivatives (5a-c).
Heterocyclisation of Schiff’s bases of 1 with thioglycolic
acid, thiomalic acid or acetic anhydride afforded novel
heterocyclic derivatives 4-thiazolidinones (7a-c), 5-carbo-
xymethyl-4-thiazolidinones (8a-c) and oxadiazoles (9a-c),
respectively. Some of the compounds showed promising
antioxidant activity in vitro and cytotoxic activity against
DLA cells and EAC cells.
Keywords: pyrazole, pyrazolone, thiazolidin-4-one, oxadia-
zole, antioxidant activity
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EXPERIMENTAL
Melting points were determined in open capillaries and were uncorrected. IR spectra
(KBr discs) were recorded on a JASCO FT/IR-410 spectrophotometer (Japan). 1H NMR
spectra were recorded on a Bruker 300 MHz NMR spectrometer (Switzerland). Mass
spectra were recorded on LC-MS/MS (API-4000), MDS SCIEX (Canada). Microanalysis
was done on a Perkin-Elmer model 2400 CHN analyser (USA). The purity of all com-
pounds was established by single spot on the TLC plates (Merck, Germany). Iodine va-
pour was used as developing agent. The solvent system used was toluene: methanol (3:7).
The starting material 4-methylcoumarinyl-7-oxyacetic acid hydrazide (1) was pre-
pared according to a literature procedure (11). 3-(Arylazo)-2,4-pentanediones (2a-c) and
ethyl-2-(substitutedphenyl) hydrazono-3-oxobutyrates (4a-c) were prepared according to
reported procedures (12–14). Synthetic pathway of newly synthesised compoundsies
presented in Scheme 1 and their physicochemical and spectral data are given in Tables I
and II.
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Table II. Spectral data of synthesised compounds




2.41 (s, 3H, CH3 of coumarin), 2.51 (s, 3H, CH3 of phenyl substituent),
3.35–3.48 (m, 6H, CH3 of pyrazole ring), 4.88 (s, 2H, OCH2), 6.25 (s, 1H,
CH of coumarin), 7.23–7.74 (m, 7H, Ar-H) m/z 431.6 (M+1)+ (14), 219.2




2.19 (s, 3H, CH3 of coumarin), 2.50 (s, 3H, CH3 at C3 of pyrazole), 3.37
(s, 3H, CH3 at C5 of pyrazole), 4.79 (s, 2H, OCH2), 6.25 (s, 1H, CH of




2.41 (s, 3H, CH3 of coumarin), 2.51 (s, 3H, CH3 at C3 of pyrazole), 3.37
(s, 3H, CH3 at C5 of pyrazole), 4.79 (s, 2H, OCH2), 6.25 (s, 1H, CH of




2.27 (s, 3H, CH3 of phenyl substituent), 2.38 (s, 3H, CH3 of coumarin),
3.31(s, 3H, CH3of pyrazolone), 4.73 (s, 2H, OCH2), 6.22 (s, 1H, CH of
coumarin), 6.85–7.74 (m, 7H, Ar-H), 10.32 (s, 1H, NH) m/z 431.6 (M+)




2.52 (s, 3H, CH3 of coumarin), 2.63 (s, 3H, CH3 of pyrazolone), 4.87 (s,
2H, OCH2), 6.38 (s, 1H, CH of coumarin), 7.08–7.87 (m, 8H, Ar-H),




2.41 (s, 3H, CH3 of coumarin), 2.52 (s, 3H, CH3 of pyrazolone), 4.73 (s,




2.32 (s, 3H, CH3 of phenyl substituent), 2.41 (s, 3H, CH3 of coumarin),
4.78 (s, 2H, OCH2), 5.12 (s, 1H, CH), 6.24 (s, 1H, CH of coumarin),
7.32–8.71 (m, 7H, Ar-H), 10.01 (s, 1H, NH) m/z 351.2 (M+1)+ (14),
219.2 (100), 189.0 (42), 175.2 (32)
6b 3210, 1672,
1685, 1267
2.41(s, 3H, CH3 of coumarin), 4.83 (s, 2H, OCH2), 4.98 (s, 1H, CH), 6.36
(s, 1H, CH of coumarin), 7.08–7.87 (m, 8H, Ar-H), 10.30 (s, 1H, NH)
6c 3175, 1654,
1692, 1270
2.34 (s, 3H, CH3 of coumarin), 4.78 (s, 2H, OCH2), 5.01 (s, 1H, CH), 6.42




2.34 (s, 3H, CH3 of phenyl substituent), 2.41 (s, 3H, CH3 of coumarin),
3.35 (s, 2H, CH2), 4.80 (s, 2H, OCH2), 5.28 (s, 1H, CH), 6.24 (s, 1H, CH
of coumarin), 6.97–7.75 (m, 7H, Ar-H), 10.28 (s, 1H, NH) m/z 425.3




2.41 (s, 3H, CH3 of coumarin), 3.41 (s, 2H, CH2), 4.78 (s, 2H, OCH2),
5.31 (s, 1H, CH), 6.25 (s, 1H, CH of coumarin), 6.99–7.74 (m, 8H, Ar-H),




2.41 (s, 3H, CH3 of coumarin), 2.50 (s, 2H, CH2), 5.25 (s, 2H, OCH2),
6.25 (s, 1H, CH), 6.87 (s, 1H, CH of coumarin), 7.71–8.32 (m, 7H, Ar-H),
10.31 (s, 1H, NH) m/z 429.2 (M+1)+ (12), 355.2 (100), 291.1 (64),




2.33 (s, 3H, CH3 of phenyl substituent), 2.40 (s, 3H, CH3 of coumarin),
2.49–2.51 (d, 2H, CH2), 4.80 (s, 2H, OCH2), 5.30 (s, 1H, CH-N), 6.24
(s, 1H, CH of coumarin), 6.9–7.8 (m, 7H, Ar-H), 7.75–7.98 (t, 1H, CH),
8.30 (s, 1H, NH), 10.30 (s,1H, COOH) m/z 483.2 (M+) (44), 351.2 (85),
291.1 (11), 249.1 (12), 149.2 (64)
Synthesis of 1-(4-methylcoumarinyl-7-oxyacetyl)-3,5-dimethyl-4-(arylazo) pyrazoles
(3a-c)
A mixture of appropriate 3-(arylazo)-2,4-pentanediones (2a-c) (0.001 mol) and com-
pound 1 (0.248 g, 0.001 mol) in glacial acetic acid (10 mL) was refluxed for 10 h. The re-
sultant solution was cooled and allowed to stand overnight. The resultant solid was col-
lected by filtration, purified by repeated washings with acetic acid and recrystallised from
acetic acid.
Synthesis of 1-(4-methylcoumarinyl-7-oxyacetyl)-3-methyl-4-(substituted phenyl)
hydrazono-2-pyrazolin-5-ones (5a-c)
Ethyl-2-(substituted phenyl)hydrazono-3-oxobutyrates (4a-c) (0.02 mol) were dis-
solved in glacial acetic acid (20 mL) and 4-methylcoumarinyl-7-oxyacetic acid hydrazide
(0.496 g, 0.002 mol) dissolved in 20 mL of glacial acetic acid was added. The mixture was
refluxed for 4 h, cooled and then allowed to stand overnight. The resultant solid was fil-
tered, dried and then recrystallised from ethanol. The purity of all compounds was es-
tablished by single spot on the TLC plates as described above.
Synthesis of 4-methylcoumarinyl-7-oxyacetic acid [(substituted phenyl) methylene]
hydrazides (6a-c)
A mixture of compound 1 (2.48 g, 0.01 mol), glacial acetic acid (20 mL) and substi-
tuted benzaldehyde (0.01 mol) was refluxed for 8 h. The contents were then poured
onto crushed ice. The resultant solid was filtered and recrystallised using glacial acetic
acid.
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2.41 (s, 3H, CH3 of coumarin), 2.50–2.51 (d, 2H, CH2), 4.70 (s, 2H,
OCH2), 5.31 (s, 1H, CH-N), 6.24 (s, 1H, CH of coumarin), 6.97–8.02 (m,




2.41 (s, 3H, CH3 of coumarin), 2.50–2.62 (d, 2H, CH2), 4.78 (s, 2H,
OCH2), 5.31 (s, 1H, CH-N), 6.25 (s, 1H, CH of coumarin), 6.98–7.80 (m,
7H, Ar-H), 8.02 (t, 1H, CH), 8.33 (s, 1H, NH), 11.69 (s,1H, COOH) m/z




2.4 (s, 3H, CH3 of phenyl substituent), 2.5 (s, 3H, COCH3), 3.4 (s, 3H,
CH3 of coumarin), 5.3 (s, 2H, OCH2), 6.2 (s, 1H, CH of coumarin), 7.1




2.4 (s, 3H, COCH3), 2.5 (s, 3H, CH3 of coumarin), 4.8 (s, 2H, OCH2), 6.2




2.4 (s, 3H, COCH3), 2.5 (s, 3H, CH3 of coumarin), 5.3 (s, 2H, OCH2), 6.2
(s, 1H, CH of coumarin), 7.1 (s, 1H, CH), 7.3–8.1 (m, 7H, Ar-H) m/z
397.1 (M+1)+ (88), 355.1 (100), 193.3 (6), 163.2 (49), 122.2 (24)
Synthesis of 2-(substituted phenyl)-3-(4-methylcoumarinyl-7-oxyacetamido)-
-4-thiazolidinones (7a-c)
A homogenous mixture of compounds 6a-c (0.01 mol) and thioglycollic acid (0.92 g,
0.01 mol) in 20 mL of glacial acetic acid was refluxed for 10 h. The reaction mixture was
triturated with sodium bicarbonate solution (10 %). The resultant neutral solid was pou-
red onto crushed ice. The separated product was filtered off, washed with water, dried
and recrystallised from ethanol.
Synthesis of 2-(substituted phenyl)-3-(4-methylcoumarinyl-7-oxyacetamido)-
-5-carboxymethyl-4-thiazolidinone (8a-c)
A homogenous mixture of compounds 6a-c (0.01 mol) and thiomalic acid (1.52 g,
0.01 mol) in glacial acetic acid (20 mL) was refluxed for 10 h. The reaction mixture was
dissolved in sodium bicarbonate solution, reprecipitated by hydrochloric acid (10 %)
and recrystallised from ethanol.
Synthesis of 3-acetyl-2-(substituted phenyl)-5-(4-methylcoumarinyl-7-oxymethyl)-
-2,3-dihydro-1,3,4-oxadiazoles (9a-c)
A mixture of compounds 6a-c (0.01 mol) and acetic anhydride (5 mL) was refluxed
for 2 h. The mixture was cooled, poured onto crushed ice and allowed to stand at room
temperature overnight. The separated solid was washed with water, dried and recrysta-
llised from acetone-ethanol (1:1).
In vitro cytotoxic activity towards DLA cells and EAC cells
The synthesised compounds 3a-c, 5a-c, 7a-c, 8a-c and 9a-c were tested for their cyto-
toxicity in vitro, in comparison with 5-fluorouracil as reference drug, against DLA cells
and EAC cells. Dalton’s lymphoma ascites (DLA) and Ehrlich ascite carcinoma (EAC)
cells were procured from Adayar Cancer Institute, Chennai, India.
DLA and EAC cells (1 ´ 106) were incubated with synthesised compounds at con-
centrations of 50 mg mL–1 and 100 mg mL–1, respectively, in 1 mL phosphate buffered sa-
line (incorporated with 10 mL DMSO) at 37 °C for 3 h. Viable cells were counted in a
haemocytometer using the trypanblue exclusion method (15). Experiments were carried
out in triplicate. Results are given in Table III.
Antioxidant activity
Free radical scavenging activity of the test compounds 3a-c, 5a-c, 7a-c, 8a-c and 9a-c
was studied by the diphenylpicryl hydrazyl (DPPH) assay method (3–6). Methanolic so-
lution of the synthesised compounds (1.5 mL, 0.2 mmol L–1) was added to 1.5 mL (0.2
mmol L–1) solution of DPPH radical in methanol (final concentration of DPPH and syn-
thesized compounds was 0.1 mmol L–1). The mixture was shaken vigorously allowed to
stand for 30 min, absorbance at 517 nm was determined and the percentage of scaveng-
ing activity was calculated.
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Ascorbic acid was used as the reference compound. All tests and analyses were
done in three replicates and the results were averaged. Results are presented in Table IV.
RESULTS AND DISCUSSION
Chemistry
Formation of compounds 3a-c and 5a-c was confirmed by the presence of character-
istic ring C=N stretching at n between 1606–1623 cm–1 in the IR spectrum. Compound
3a, which was representative of pyrazoles, showed m/z 431.6 (M+1)+ and compound 5a,
which represented pyrazolones, showed m/z 431.6 (M+). Similarly, elemental analysis data
together with 1H NMR data supported the proposed structure for compounds 3a-c and
5a-c given in Tables I and II.
Formation of 4-thiazolidinones (7a-c) and 5-carboxymethyl-4-thiazolidinones (8a-c)
was confirmed by IR spectra, which showed ring C=O stretching characteristic of thia-
zolidinone ring in the range of n 1709–1737 cm–1. 1H NMR for 7a-c showed CH2 protons
of the thiazolidinone ring between d 3.35–3.41 ppm as the singlet signal and d 5.28–5.31
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Table III. Cytotoxic activity of synthesised compounds
Compd.
Cytotoxicity (%)a
















Negative control – –
5-Fluorouracil 98.8 99.5
a Results are the mean of three experiments.
b Compounds were tested at 100 mg mL–1 for cytotoxicity against DLA cells.
c Compounds were tested at 50 mg mL–1 for cytotoxicity against EAC cells.
ppm for CH proton of the thiazolidinone ring as a singlet signal. Compounds 7a and 7c
representative of thiazolidine-4-ones showed (M+1)+ peaks at m/z of 425.3 and 429.2, re-
spectively, in mass spectra. 1H NMR for 5-carboxymethyl-4-thiazolidinones (8a-c) showed
a singlet in the spectra in the range d 5.30–5.31 ppm, indicating the presence of CH-N of
thiazolidinones. M+ peak and (M+1)+ peak at 483.2 and 487.3 were obtained in the mass
spectra of representative compounds 8a and 8c, respectively.
IR spectra of compounds 9a-c had different characteristics since they showed no
N-H stretching bands, but C-O stretching in the 1054–1078 cm–1 region, which could be
attributed to C-O stretching of oxadiazole nucleus. 1H NMR spectra of 9a,b,c showed a
singlet in the spectra in the range d 7.10, 7.04, 7.09 ppm indicating CH resonance of the
oxadiazoline ring in accord with the literature (10). The mass spectrum of 9c showed the
molecular ion peak at m/z 397.1 (M+1)+.
Cytotoxicity studies
5-Fluorouracil, which was used as standard cytotoxic agent, exhibited cytotoxicity
of 98.8 % against DLA cells at 100 mg mL–1 and 99.5 % against EAC cells at a 50 mg mL–1
concentration. The results of short term in vitro cytotoxicity studies against DLA cells
showed that compounds 3a, 3c, 5a, 5b, 7a, 7b, 8c and 9c exhibited more than 50 % cyto-
toxicity at a 100 mg mL–1 concentration. Compound 5b showed the highest cytotoxicity
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Table IV. Antioxidant activity of synthesised compounds


















a Results are mean of three different experiments.
– Denotes very low antioxidant activity (scavenging activity < 10 %).
of 90.8 %. The results of short term in vitro cytotoxicity studies against EAC cells showed
that compounds 3b, 5b, 5c, 8a, 8b, 9a and 9b exhibited more than 50 % cytotoxicity at a
concentration of 50 mg mL–1. Compounds 5b, 5c and 8b showed the highest percentage
of cytotoxicity of 97.5, 90.2 and 97.3 %, respectively.
Antioxidant activity
Concentration of the test compounds and ascorbic acid were of 0.1 mmol L–1. Among
the pyrazoles, compounds 3a and 3b with p-methyl phenyl substituent and unsubsti-
tuted phenyl substituent, respectively, showed more than 50 % antioxidant activity. It
was interesting to note that thiazolidine-4-ones showed negligible antioxidant activity of
less than 10 % free radical scavenging capacity. Among 5-carboxymethyl-4-thiazolidino-
nes, compound 8b with unsubstituted phenyl substituent showed more than 95 % anti-
oxidant activity which was comparable to that of the standard ascorbic acid (96 %). 3-Ace-
tyloxadiazoles 9a and 9b showed more than 50 % antioxidant activity. Antioxidant
activity of pyrazoles and 5-carboxymethyl-4-thiazolidinones followed the following or-
der: unsubstituted phenyl derivative > p-methyl phenyl derivative > p-fluorophenyl de-
rivative. Pyrazolin-5-ones and 3-acetyloxadiazole showed antioxidant activity in the de-
scending order: p-methyl phenyl derivative > unsubstituted phenyl derivative >
p-fluorophenyl derivative. Irrespective of the type of heterocyclic nucleus, it was ob-
served that p-fluorophenyl derivatives exhibited the lowest antioxidant activity among
compounds in the respective series.
Structure activity relation
(i) Coumarin derivatives with different heterocyclic nuclei having unsubstituted
phenyl group exhibited cytotoxicity against DLA cells in the descending order of po-
tency: pyrazolin-5-one derivative > thiazolidin-4-one derivative > pyrazole derivative >
5-carboxymethyl-4-thiazolidinone derivative > 1,3,4-oxadiazole derivative, as it is evi-
dent from the percentage cytotoxicity of 5b, 7b, 3b, 8b and 9b, respectively (Table III).
The presence of p-fluorophenyl substituent increased the cytotoxicity of 5-carboxymethyl-
-4-thiazolidinone derivative, 1,3,4-oxadiazole derivative and azopyrazoles against DLA
cells compared to the compounds having unsubstituted phenyl ring or p-methylphenyl
substituent in the respective series. The presence of p-fluorophenyl substituent decreased
the cytotoxicity of hydrazonopyrazolin-5-ones and thiazolidin-4-one derivatives against
DLA cells compared to those having unsubstituted phenyl ring or p-methyl phenyl sub-
stituent in the respective series.
(ii) Coumarin derivatives with different heterocyclic nuclei having unsubstituted
phenyl group exhibited cytotoxicity against EAC cells in the descending order of potency:
pyrazolin-5-one derivative > 5-carboxymethyl-4-thiazolidinone derivative > azo pyrazole
derivative > 1,3,4-oxadiazole derivative > thiazolidin-4-one derivative, as seen from the
cytotoxicity of 5b, 8b, 3b, 9b and 7b, respectively (Table III). The presence of p-fluoro-
phenyl substituent increased the cytotoxicity of azopyrazoles and hydrazonopyrazolin-
-5-ones against EAC cells compared to the compounds having p-methylphenyl substituent
in the respective series. The presence of p-fluorophenyl substituent decreased the cyto-
toxicity of thiazolidin-4-one derivative, 5-carboxymethyl-4-thiazolidinone derivative and
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1,3,4-oxadiazole derivative against EAC cells compared to those having p-methylphenyl
substituent in the respective series.
(iii) Coumarin derivatives with different heterocyclic nuclei having unsubstituted
phenyl group exhibited antioxidant activity in the descending: 5-carboxymethyl-4-thia-
zolidinone derivative > pyrazole derivative > 1,3,4-oxadiazole derivative > pyrazolin-5-one
derivative > thiazolidin-4-one derivative (Table IV). Substitution of unsubstituted phenyl
group at the fourth position of 5-carboxymethyl-4-thiazolidinone derivative (8b) and un-
substituted phenylazo substituent at the third position of pyrazolone derivative (3b) im-
parted higher antioxidant activity than substitution with p-methylphenyl or p-fluoro-
phenyl group. Substitution of p-fluoro substituent on phenyl ring produced compounds
with lower antioxidant activity than the remaining compounds in the respective series,
as seen for compounds 3c, 5c, 7c, 8c and 9c.
CONCLUSIONS
Results of antioxidant activity show that compound 8b (0.1 mmol L–1) (phenyl de-
rivative of 5-carboxymethyl-4-thiazolidinone) exhibited the highest free radical scaveng-
ing activity (95 %), which was comparable to that of standard ascorbic acid (0.1 mmol
L–1) (96 %). Cytotoxicity studies against tumour cells showed compound 5b (phenyl de-
rivative of pyrazolin-5-one) to be a good cytotoxic agent against DLA cells at a 100 mg
mL–1 concentration and compounds 5b and 8b (phenyl derivative of 5-carboxymethyl-
-4-thiazolidinones) to be potent cytotoxic agents against EAC cells at a 50 mg mL–1 con-
centration. Further studies aimed at development of an effective antioxidant can insolve
compound 8b, and compounds 5b and 8b can be subjected to further in vivo anticancer
studies. Since antioxidants have a valuable role in the prophylaxis of cancer, it could be
concluded that compound 8b can be selected as the lead moiety in the analogue design-
ing process of developing an ideal antineoplastic agent.
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S A @ E T A K
Sinteza kumarinskih heterocikli~kih derivata s antioksidativnim djelovanjem i in
vitro citotoksi~no djelovanje na tumorske stanice
PARAMESWARAN MANOJKUMAR, THENGUNGAL KOCHUPAPPY RAVI i GOPALAKRISHNAN SUBBUCHETTIAR
Cilj rada bio je sintetizirati kumarinske heterocikli~ke derivate i razjasniti njihovu
potencijalnu ulogu kao antioksidativnih i citotoksi~nih agenasa na tumorske stanice
Daltonovog limfoma (DLA) i Ehrlichove tumorske stanice (EAC). U radu je opisana sin-
teza kumarinskih derivata s pirazolskim, pirazolonskim, tiazolidin-4-onskim, 5-karbo-
ksimetil-4-tiazolidinonskim i 3-acetil-1,3,4-oksadiazolskim prstenom. Hidrazid 4-metil-
kumarinil-7-oksioctene kiseline (1) dao je u reakciji s derivatima arilazopropana ili
hidrazono-3-oksobutirata derivate pirazola (3a-c) i pirazolona (5a-c). Heterociklizacijom
Schiffovih baza 1 s tioglikolnom kiselinom, tiojabu~nom kiselinom ili anhidridom octene
kiseline nastali su heterocikli~ki derivati 4-tiazolidinoni (7a-c), 5-karboksimetil-4-tiazoli-
dinoni (8a-c) i oksadiazoli (9a-c). Neki od spojeva pokazali su obe}avaju}e rezultate u in
vitro testovima za antioksidativno i citostatsko djelovanje na DLA i EAC stanicama.
Klju~ne rije~i: pirazol, pirazolon, tiazolidin-4-on, oksadiazol, antioksidativno djelovanje
Department of Pharmaceutical Chemistry, College of Pharmacy, Sri Ramakrishna Institute of Paramedical
Sciences, Coimbatore-641044, Tamilnadu, India
170
P. Manojkumar et al.: Synthesis of coumarin heterocyclic derivatives with antioxidant activity and in vitro cytotoxic activity against
tumour cells, Acta Pharm. 59 (2009) 159–170.
